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Oral Presentations 17a significant proportion of patients with high-risk hematological
disease. This is the first report containing data on long-term toxicity
and disease control after any strategy of donor graft manipulation to
selectively reduce HLA-mismatched alloreactivity.
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FEASIBILITY OF UNRELATED UMBILICAL CORD BLOOD TRANSPLANTA-
TION IN CONGENITAL CHILDHOOD DISEASES
Martinez, C.1, Tolar, J.1, Wagner, J.E.1, Tan, P.-L.1, DeFor, T.1,2,
Baker, K.S.1, Orchard, P.J.1. 1University of Minnesota, Minneapolis,
MN; 2University of Minnesota, Minneapolis, MN.
An HLA-matched sibling donor has been the initial choice for
children requiring allogeneic hematopoietic cell transplant
(HCT). However, less than 30%HCT patients have a matched re-
lated donor (MRD). In the past decade, umbilical cord blood (UCB)
transplantation has emerged as an attractive alternative for patients
without a MRD. Recent studies have shown the advantages of using
UCB over bone marrow as an alternative graft source for children
with acute leukemias. However, there is less information available
regarding the utilization of unrelated UCB transplantation for chil-
dren with non-malignant diseases. We report the use of an unre-
lated UCB myeloablative transplantation in fifty-five consecutive
children with a median age of 2.6 years (range, 0.2–40.6 years)
with Wiskott-Aldrich syndrome, Chediak-Higashi syndrome, he-
mophagocytic lymphohistiocytosis, langerhans cell histiocytosis,
osteopetrosis, Diamond-Blackfan anemia, Hurler syndrome,Maro-
teaux-Lamy, a-mannosidosis, cerebral X-linked adrenoleuko-
dystrophy, metachromatic leukodystrophy and globoid-cell
leukodystrophy transplanted over 11.5 year period (1994–2006).
Patients received grafts matched at 6 (14%), at 5 (56%), or at 4
HLA alleles (30%). The median total nucleated cell dose and the
median CD341 cell dose were 5.4  107/kg and 4.2  105/kg, re-
spectively. The median time to neutrophil recovery was 20 days
(range, 10–45 days) and the incidence of neutrophil recovery by
day 42 was 86%. The incidence of platelet recovery by 6 months
was 73%. In the group of immune or hematological disorders, 6
of 10 patients achieved complete donor chimerism by day 21. In
the metabolic disorders group, 8 of 13 patients achieved a complete
donor chimerism at a median of 21 days and 3 additional patients at
a median day of 95 days. In the leukodystrophy group, 6 of 12 pa-
tients achieved completed donor chimerism by day 21 and 4 patients
achieved complete donor chimerism at a median of 120.5 days. The
incidences of grade II-IV and grade III-IV acute GvHD were 34%
and 12%, respectively. Chronic GvHD was observed in only 5% of
cases. The overall survival was 62% at 2-years. These results dem-
onstrate the usefulness of unrelated UCB as an alternate stem cell
source for patients lacking an HLA matched related or unrelated
donor. The use of unrelated UCB transplantation creates new op-
portunities in the treatment of non-malignant diseases requiring ex-
pedient HCT in order to prevent irreversible disease progression.
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OUTCOMES OF A PROSPECTIVE TRIAL OF NMDP-FACILITATED UNRE-
LATED DONOR (UD) PBSC HEMATOPOIETIC CELL TRANSPLANTATION
(HCT) FOR LEUKEMIA ANDMYELODYSPLASIA: COMPARABLE SURVIVAL
REGARDLESS OF REGIMEN INTENSITY AND IMPROVED SURVIVALWITH
HIGHER CELL DOSES
Pulsipher, M.A.1, Chitphakdithai, P.2, Logan, B.3, Leitman, S.4,
Anderlini, P.5, Klein, J.3, Horowitz, M.3, Miller, J.2, King, R.2,
Confer, D.2. 1University of Utah, Salt Lake City, UT; 2Nat Marrow
Donor Prog, Minneapolis, MN; 3Center for International Blood and
Marrow Transplant Research, Milwaukee, WI; 4NIH, Bethesda, MD;
5MD Anderson Cancer Center, Houston, TX.
We report outcomes of 932 recipients (rcpts) of UD PBSCHCT
facilitated by NMDP from 1999 through 2003 (median f/u 3.3 yrs).
Indications were AML (419 rcpts), ALL (185 rcpts), CML (134
rcpts), and MDS (194 rcpts). Preparative regimens included mye-
loablative (MA, N 5 611), reduced intensity (RI, N 5 160), and
non-myeloablative (NMA, N5 161). Distributions of HLA-match
grade, CMV status, Karnofsky scores (KS), and donor characteris-
tics were similar between the preparative regimens, however, fewer
rcpts with advanced disease received NMA (p5 0.035), while morercpts with coexisting diseases received RI and NMA regimens (p\
0.001). The age of rcpts receiving RI and NMA regimens was sub-
stantially higher than rcpts receiving MA regimens (median RI 56
yo, NMA 57 yo, MA 38 yo, p\0.001). Optimal cell dose cutpoints
for TNC,MNCandCD341were determined based onMartingale
residuals from Cox regression analyses. For MA rcpts, CD341
counts .3.8  106/kg improved day 125 neutrophil and day 160
platelet engraftment; higher infused TNC doses (.6.9  108/kg)
predicted decreased grade III-IV aGVHD, while improved overall
survival (OS) and reduced TRM (RR 0.55) were seen with MNC
doses .4.4  108/kg. For RI and NMA rcpts, OS was higher and
TRM was decreased in those receiving .3.8  106 CD341cells/
kg. Of note, cGVHD was not increased with higher cell doses in
rcpts of any type of preparative regimen. Additional predictors of
improved OS included early disease, and for MA rcpts only,
HLA-matched donors, KS $ 90, and CsA-based GVHD prophy-
laxis. Three year OS and DFS of rcpts receiving MA, RI, and
NMA approaches were similar (33, 35, and 32% OS; 33, 30, and
29% DFS: MA, RI, and NMA, respectively). Higher risk of relapse
at 3 yrs in RI and NMA approaches (35, 37 vs. 24% RI, NMA, MA,
respectively, p\ 0.001) was offset by higher 3 yr TRM using MA
regimens (43 vs. 34, 34% MA, RI, NMA, respectively, p 5 0.008).
Sub-analyses of 1) rcpts with AML-CR1, 2) rcpts with AML/
MDS/CML (excluding ALL), or 3) rcpts between the ages of 40–
60 with AML/MDS also showed similar survival with MA vs. RI
vs. NMA approaches. In summary, rcpts of UDPBSCHCT receiv-
ing preparative regimens differing in intensity experienced similar
survival. Higher cell doses resulted in more rapid engraftment,
less severe aGVHD (MA rcpts), and better 3 year OS (37 vs. 18%,
MA; 36 vs. 21% RI/NMA, p\ 0.001), but did not increase the
risk of cGVHD.IMMUNE RECONSTITUTION41
PRE-TRANSPLANT ADMINISTRATION OF KERATINOCYTE GROWTH FAC-
TOR AFFECTS PERIPHERAL T-CELL HOMEOSTASIS THROUGH IN-
CREASED RECENT THYMIC EMIGRANT EXPORT AND AFFECTS THE
COURSE OF MURINE CHRONIC GRAFT-VS.-HOST DISEASE
Chu, Y.-W., Bodnar, D., Singh, N., Gress, R. National Cancer Institute,
Bethesda, MD.
Accelerated recovery of thymic function following allogeneic he-
matopoietic stem cell transplantation (allo-HSCT) not only pro-
vides a sufficiently broad repertoire of T-cell responses to
pathogens, but also is thought to play a role in affecting the outcome
of graft-vs.-host disease (GVHD) through the restoration of central
tolerance and/or the production of regulatory cell populations that
may blunt the effect of donor-derived alloreactive T-cell popula-
tions. Keratinocyte growth factor (KGF) has been shown in murine
models to accelerate thymic function and ameliorate acute GVHD,
but it is unclear whether the latter involves a thymic-dependent
mechanism of increased T-cell production and/or cytoprotection
of epithelial cells in target organs of GVHD. We examined the ef-
fect of pre-transplant administration of KGF in the B10.D2 into
BALB/c murine model of chronic GVHD (cGVHD). KGF treated
mice had significantly increased thymic function as assessed by enu-
meration of thymocyte populations, analysis of thymic cytoarchi-
tecture, and enumeration of peripheral T-cell subsets and recent
thymic emigrants (RTE). Significantly, enhanced export of RTE
by KGF decreased peripheral T-cell homeostatic expansion and
downregulated expression of activation markers, suggesting that
RTE effectively compete with post-thymic T-cells for limited cyto-
kines and contact-dependent niches post-allo-HSCT. Parallel ex-
periments in thymectomized recipients receiving KGF exhibited
no changes in cell cycle profiles or activation profiles of peripheral
T-cells. Pre-transplant KGF administration improved clinical
cGVHD outcomes in both thymus-intact and thymectomized re-
cipients. However, there were no observable differences in the
course of cGVHDbetweenKGF treated thymus intact and thymec-
tomized mice, suggesting that enhanced thymic function by KGF
did not provide for any additional benefit to the cytoprotective ef-
fects of KGF. One contributing factor for this observation was
18 Oral Presentationsthe inability of KGF treatment to increase peripheral regulatory T-
cell numbers. In summary, pre-transplant administration of KGF
can accelerate thymic recovery post allo-HSCT and that the in-
creased export of newly generated T-cells can blunt peripheral ex-
pansion of post-thymic T-cells. However, this thymus-dependent
effect of KGF is insufficient to further ameliorate cGVHD. Never-
theless, the results suggest a potentially important role of KGF in
immune reconstitution and modulation of cGVHD post-allo-
HSCT.42
IN VIVO EXPANSION OF CD41FOXP31 REGULATORY T CELLS MAY
CONTRIBUTE TO CONTROL OF ACUTE GVHD AFTER HLA-MISMATCHED
ALLOANERGIZED HSCT
Davies, J.1, Yuk, D.1, Brennan, L.2, Nadler, L.1, Guinan, E.2. 1Dana
Farber Cancer Institute, Boston, MA; 2Dana Farber Cancer Institute,
Boston, MA.
Many strategies have been explored to selectively remove allor-
eactive donor T cells to prevent Graft-versus-Host Disease
(GvHD) without impairing immune reconstitution after hemato-
poietic stem cell transplantation (HSCT). An alternative approach
is allostimulation of donor T cells with costimulatory blockade
(CSB) rendering allospecific cells anergized (hyporesponsive to sub-
sequent alloantigenic challenge). Murine and human data suggest
that induction of alloanergy involves cell-mediated suppression, re-
quiring the presence of CD41CD251 regulatory T cells (Tregs).
We conducted a pilot study of haploidentical alloanergized
HSCT after CSB, and measured reconstitution of Treg by intracel-
lular flow cytometry. 5 patients (pts; 4 acute leukemia, one marrow
failure) underwent cyclophosphamide/TBI-conditioned haploi-
dentical HSCT with cyclosporine and methotrexate GvHD pro-
phylaxis. Donor bone marrow was incubated with irradiated
recipient peripheral blood mononuclear cells and anti-B7.1/2 anti-
bodies for 48 hours to induce alloanergy, washed and infused. All pts
engrafted with very rapid reconstitution of T cell subsets, NK cells
and immunoglobulins. All evaluable patients had a marked relative
increase in peripheral blood CD41FOXP31 cells at D 1 20–60.
CD41FOXP31 cells had a memory Treg phenotype (CD251
CD45RO1CTLA41 CD127Lo) and were predominantly HLA
DR- differentiating them from activated T cells. Despite receiving
high doses of donor T cells (median 1.8 (CD4) and 3.1 (CD8) 
107/kg) and achieving full donor chimerism, only 2 pts developed
acute GvHD, both Grade II, resolving after short courses of corti-
costeroids. All evaluable patients also had an increase in CD41 T
effector (Teff) cells with an activated phenotype
(CD251HLADR1FOXP3-) atD1 30–50. Although the antigenic
specificity of Teff was not determined, cytokine secretion may have
led to reversal of anergy and expansion of alloreactive Teff cells.
The marked in vivo expansion of Treg may represent one mecha-
nism of suppressing alloreactive Teff and achieving immunological
control of acute GvHD without impairing immune reconstitution
in pts receiving HLA-mismatched alloanergized donor T cells.
We are using a modification of this strategy in a clinical trial of de-
layed infusion of escalating doses of alloanergized donor T cells af-
ter CD34-selected haploidentical HSCT, to determine the optimal
dose of alloanergized donor T cells that abrogates acute GvHD
without impairment of immune reconstitution.43
ADMINISTRATION OF rhIL-7 INCREASES TCR REPERTOIRE DIVERSITY
THROUGH PREFERENTIAL EXPANSION OF NAIVE T CELLS
Hakim, F.T.1, Memon, S.A.1, Sportes, C.1, Zhang, H.2, Chua, K.2,
Fry, T.2, Engel, J.3, Buffet, R.3, Morre, M.3, Mackall, C.2,
Gress, R.E.1. 1National Cancer Institute, NIH, Bethesda, MD; 2Na-
tional Cancer Institute, NIH, Bethesda, MD; 3Cytheris Inc., Rockville,
MD.
Interleukin-7 (IL-7) is a multifunctional cytokine with critical
and non-redundant roles in thymopoiesis and peripheral T-cell ho-
meostasis. We previously reported preliminary results of the first
Phase I study of recombinant human IL-7 (rhIL-7), demonstratingthat two weeks of alternate day treatment with rhIL-7 produced
a marked increase in the number of CD41 and CD81 T cells.
This increase was maintained in follow up assays at 6 to 12 weeks
post treatment. Furthermore, rhIL-7 therapy disproportionately in-
creased CD271CD45RA1 naive cells, which represent the most
diverse elements of the mature T cell receptor (TCR) repertoire,
at the expense of CD27-CD45RA1/- effector populations, which
are often oligoclonal. In CD8 T cells, the proportion of naive cells
increased by 8–39% of total cells. Because of the extent of this pop-
ulation shift, we hypothesized that rhIL-7 treatment would lead to
an overall increase in TCR repertoire diversity in CD41 and
CD81 T-cells. We assessed TCR diversity using spectratype anal-
ysis on sorted CD4 and CD8 populations before and one week after
rhIL-7 therapy (day 21) in six subjects. For each patient, we deter-
mined the divergence of spectratypes in 22 BV families fromGauss-
ian-like normal donor standards and then compared the global
diversity of pre and post spectratypes byWilcoxon paired non-para-
metric analysis.Wedetermined that rhIL-7 therapy induced a statis-
tically significant increase (P\ .05) in repertoire diversity in either
the CD41, CD81, or bothT-cell populations in 4 of the 6 patients.
This enhancement in diversity was particularly remarkable in that
three of these donors were over 60 years of age, and a fourth patient
had reduced lymphocyte populations due to recent chemotherapy.
Given the short duration of therapy, the age of the patients and
the very modest change in TREC we observed, we believe this en-
hancement in diversity was due primarily to differential population
expansion, not IL-7 induced thymic output. Consistent with this in-
terpretation, we observed that a higher percentage of naive T cells
than effector T cells remained in cycle (Ki-671) and maintained el-
evated levels of anti-apoptotic Bcl-2 during IL-7 therapy.We there-
fore propose that rhIL-7 has the potential to induce T-cell growth
and enhance repertoire diversity, even in lympho-depleted patients
with limited thymopoietic capacities, by expanding naive T cell
populations.44
THE CD41CD251FOXP31 COMPARTMENT FOLLOWING CONDITION-
ING AND TRANSPLANT: HOST TREG CELLS EXPAND AND COMPRISE
THE PREDOMINANT COMPONENT FOR SEVERAL MONTHS DURING RE-
CONSTITUTION POST-HCT
Bayer, A.L., Jones, M., Urbieta, M., Chirinos, J., Schreiber, T.,
Armas, L., Thomas, M.R., Levy, R.B. University of MiamiMiller School
of Medicine, Miami, FL.
The capacity of CD41CD251Foxp31 (Treg) cells to regulate
adaptive and innate immune responses has led to studies investigat-
ing their use in novel strategies to regulate allogeneic T cell re-
sponses during hematopoietic stem cell transplants (HCT). A
fundamental clinical concern post-HCT is the reconstitution of
the lymphoid compartment, particularlyT cells which can be excep-
tionally delayed. We have previously found that host Treg cells can
regulate resistance to engraftment following HCT, demonstrating
that such cells survive and function at least transiently in recipients.
The present studies investigated the residual host Treg compart-
ment following varying levels of conditioning (3.0 – 14Gy TBI),
and transplant.We found that recipient CD41CD251Foxp31 cells:
1) can survive ablative as well as reduced intensity conditioning, 2)
undergo expansion (BrdU uptake/cell numbers) and 3) contribute
greatly to the Treg compartment for several months post-HCT
during which time donor derived Treg cells gradually arise and
cede this compartment. Within the first 3 weeks post-lethal condi-
tioning and HCT, 95% of the splenic CD41FoxP31 cells are pos-
itive for BrdU, vs. 40% in normal mice. Using Thy1.1 congenic
mice, the vast majority of these cells were found to be resistant
(host) Tregs. Two months post-HCT, almost 30% of the compart-
ment was still of host origin. To assess the functional capacity of the
residual Treg cell compartment, we examined development of auto-
immune disease following transplant of IL-2Rb2/2 BM into synge-
neic recipients. Autoimmune disease was prevented in B6-wt but
not T cell deficient recipients. Interestingly, the failure to transfer
autoimmune disease following IL-2Rb2/2 HCT into B6-CD4-/-
recipients was associated with the presence of a peripheral
CD81FoxP31 population not detected in B6-wt mice. This finding
